149 related articles for article (PubMed ID: 10818719)
1. Use of activated natural killer cells for tumor immunotherapy in mouse and human.
Basse PH; Whiteside TL; Herberman RB
Methods Mol Biol; 2000; 121():81-94. PubMed ID: 10818719
[No Abstract] [Full Text] [Related]
2. Natural killer cells and tumor immunity: 1987.
Hiserodt JC; Herberman RB
Year Immunol; 1989; 4():201-7. PubMed ID: 2648702
[No Abstract] [Full Text] [Related]
3. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer.
Rosenberg S
J Natl Cancer Inst; 1985 Oct; 75(4):595-603. PubMed ID: 3876465
[No Abstract] [Full Text] [Related]
4. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.
Rosenberg SA; Lotze MT
Annu Rev Immunol; 1986; 4():681-709. PubMed ID: 3518753
[No Abstract] [Full Text] [Related]
5. [A new approach to immunotherapy of cancer based on autologous T-lymphocytes].
Dosne Pasqualini C; Laguens RP
Medicina (B Aires); 1987; 47(3):307-12. PubMed ID: 3326997
[No Abstract] [Full Text] [Related]
6. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
[TBL] [Abstract][Full Text] [Related]
7. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
[TBL] [Abstract][Full Text] [Related]
8. Human and mouse "LAK" cells expanded in long-term cultures: in vitro and in vivo studies.
Kedar E; Zeira E; Lebendiker Z; Weiss DW; Katan R; Shouval D
Prog Clin Biol Res; 1987; 244():59-75. PubMed ID: 3498959
[No Abstract] [Full Text] [Related]
9. Cancer Immunotherapy by coordinated stimulation of innate lymphocytes (NK and NKT cells).
Fujii S
Rinsho Ketsueki; 2009 May; 50(5):364-74. PubMed ID: 19483396
[No Abstract] [Full Text] [Related]
10. [NK cell-based immunotherapy: new prospects and involvement of dendritic cells].
Borg C; Taieb J; Terme M; Maruyama K; Flament C; Angevin E; Zitvogel L
Bull Cancer; 2003; 90(8-9):699-705. PubMed ID: 14609759
[TBL] [Abstract][Full Text] [Related]
11. [Immunity and immunosuppression in tumor growth].
Govallo VI
Vopr Onkol; 1987; 33(4):91-9. PubMed ID: 3296437
[No Abstract] [Full Text] [Related]
12. [Immunotherapy of parenchymal tumors. Recent progress and theoretical considerations].
Marincola F; Smolik L; Annoni F; Holter WD
Minerva Chir; 1988 Jul; 43(13-14):1111-31. PubMed ID: 3054627
[No Abstract] [Full Text] [Related]
13. Adoptive cellular immunotherapy of cancer.
Winter H; Fox BA
Curr Opin Mol Ther; 1999 Feb; 1(1):89-97. PubMed ID: 11249690
[No Abstract] [Full Text] [Related]
14. Natural killer cells.
Herberman RB
Prog Clin Biol Res; 1989; 288():161-7. PubMed ID: 2470107
[No Abstract] [Full Text] [Related]
15. Natural killer cell-based immunotherapy in cancer: current insights and future prospects.
Sutlu T; Alici E
J Intern Med; 2009 Aug; 266(2):154-81. PubMed ID: 19614820
[TBL] [Abstract][Full Text] [Related]
16. Natural killer T cell-based cancer immunotherapy.
van der Vliet HJ; Balk SP; Exley MA
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):5921-3. PubMed ID: 17062661
[No Abstract] [Full Text] [Related]
17. Invariant natural killer T cells and immunotherapy of cancer.
Molling JW; Moreno M; van der Vliet HJ; van den Eertwegh AJ; Scheper RJ; von Blomberg BM; Bontkes HJ
Clin Immunol; 2008 Nov; 129(2):182-94. PubMed ID: 18783990
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J
Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
[TBL] [Abstract][Full Text] [Related]
19. The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers.
Talmadge JE; Herberman RB
Cancer Treat Rep; 1986 Jan; 70(1):171-82. PubMed ID: 3510733
[No Abstract] [Full Text] [Related]
20. Immunotherapy of cancer: the end of the beginning?
Durant JR
N Engl J Med; 1987 Apr; 316(15):939-41. PubMed ID: 3493434
[No Abstract] [Full Text] [Related]
[Next] [New Search]